Long-Term Efficacy of Diltiazem Controlled Release Versus Metoprolol in Patients with Stable Angina Pectoris

Vliegen, H.W.; Wall, Ernst E. van der; Niemeyer, M. G.; Holwerda, N. J.; Bernink, P. J. L. M.; Weerd, P. de; Bosma, A. H.; Wieken, L. R. van der; Timmermans, A. J. M.; Molhoek, G. P.; Mulder, Paul

doi:10.1097/00005344-199106189-00012

Cited by 11 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No differences in the above-mentioned efficacy variables were found between the two different preparations of diltiazem. Previously, some studies with the same CR formulation (Cardizem, Retard) on angina pectoris have been performed, which support the results of our study [5,[9][10][11][12][13][14].…”

Section: Discussionsupporting

confidence: 90%

Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris

Boman

Saetre

Karlsson

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Two preparations of diltiazem, controlled release (CR) given twice a day (b.i.d.) and plain given 4 times a day (q.i.d.), were compared in a multicentre, double-blind, crossover study in 41 patients with stable angina pectoris. Therapeutic efficacy was assessed with maximal exercise tests, patient recordings on nitroglycerine consumption and angina attacks. No significant differences between the CR and plain tablets were seen in any of the efficacy variables. Maximal workload significantly increased from 127 W on placebo to 146 W on CR tablets and to 147 W on plain tablets. Anginal attacks/week significantly decreased from 11.7 on placebo to 4.9 on CR tablets and to 5.0 on plain tablets. Consumption of nitroglycerine tablets/week significantly decreased from 6.3 on placebo to 2.6 and to 3.4 on CR and plain-tablets, respectively. The number or the seriousness of the adverse events did not differ between the groups. The results imply that diltiazem CR b.i.d. is equally potent and safe as conventional diltiazem q.i.d. in the control of stable angina pectoris.

show abstract

Section: Discussionsupporting

confidence: 90%

Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris

Boman

Saetre

Karlsson

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…These studies show no major diVerences between the main classes of drug treatment. [8][9][10][11][12][13][14][15] There is also no evidence that combination treatment is more eVective than monotherapy, 16 17 and no evidence of major treatment related diVerences in health related quality of life.…”

Section: Relief Of Symptomsmentioning

confidence: 99%

Effective management of stable angina

Petticrew¹,

Sculpher²,

J³

et al. 1998

Quality and Safety in Health Care

View full text Add to dashboard Cite

“…However, differences in patient selection, study design, and drug dosages all prevent critical comparisons. Specific comparisons were β blockers and dihydropyridines,67 68 69 70 71 β blockers and diltiazem or verapamil,72 73 74 and studies with three drugs 75 76. Within the time frame of our search there was no compelling evidence to choose one β blocker over another (I) 77 78 79.…”

Section: Age Limitsmentioning

confidence: 99%

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina

Eccles¹

1996

BMJ

View full text Add to dashboard Cite

Long-Term Efficacy of Diltiazem Controlled Release Versus Metoprolol in Patients with Stable Angina Pectoris

Cited by 11 publications

References 0 publications

Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris

Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris

Effective management of stable angina

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina

Contact Info

Product

Resources

About